Monday, December 22, 2014 Last update: 3:33 PM - Covering Large & Obscure Tech Companies Since 1996

BTIG Expands Healthcare Research Coverage

Companies mentioned in this article: BTIG, LLC

NEW YORK -- (BUSINESS WIRE) -- BTIG LLC, a global financial services firm specializing in institutional trading and related brokerage services, announced today that Hartaj Singh has joined the firm as a Director and Biotechnology Analyst. Singh has broad experience in the field of healthcare, having covered global biotechnology and international pharmaceutical stocks during his nine years as both a sell- and buy-side research analyst. At BTIG, Hartaj will focus on U.S. biotechnology firms and other global biotechnology and pharmaceuticals stocks that are in their competitive landscape.

“Hartaj’s insight in the biotechnology sector, his understanding sentiment and his analysis of both long and short strategies will provide yet another differentiating factor for our research effort,” said Scott Kovalik, Co-Founder of BTIG. “As we expand our research offering, it is key that we bring on top talent to match the level of expertise that our current research team affords our clients, and Hartaj certainly meets that high standard.”

Hartaj is returning to the sell-side after several years as a buy-side analyst at Visium Asset Management, where he covered the European and international pharmaceutical and biotechnology sectors. Prior to that, at Lehman Brothers, Hartaj assisted in the re-launch of the US large-cap biotechnology research franchise. In addition, Hartaj assisted healthcare clients with critical strategic, clinical and operational projects as a Managing Consultant with Navigant Consulting’s Life Sciences practice from 2003 to 2005. Prior to working on the sell- and buy-side, Hartaj worked for almost 10 years in the industry with experience in clinical drug development, sales and marketing and business development. He assisted on U.S. development efforts for Keppra while at ClinTrials Research from 1993 through 1999 and eventually was the Clinical Project Manager on the New Drug Application with FDA in late 1998. Hartaj received a Bachelor of Arts from Case Western Reserve University and an MBA from the Fuqua School of Business at Duke University.

Hartaj’s hire is BTIG’s latest move to expand its research offerings, which now includes a global strategist, a technical strategist, seven publishing analysts covering the consumer, financials, healthcare, media, entertainment, cable and satellite, internet, communications equipment, telecom services and special situations sectors. This month BTIG also hired Dane Leone as a Diagnostics and Life Sciences Analyst.

About BTIG

BTIG, LLC is a global financial services company offering products and services across Equity Trading, Derivatives, Fixed Income, Futures & Commodities, Foreign Exchange, Convertible/Preferred Securities, Corporate Access, Equity Research, Capital Markets, Prime Brokerage, Electronic Trading and Outsource Trading. With U.S. offices located in New York, San Francisco, Dallas, Boston, Chicago, Los Angeles, Purchase, Red Bank and Atlanta, and overseas affiliates located in London, Hong Kong, Singapore and Sydney, BTIG, including through its affiliates, employs more than 450 professionals worldwide.


Copyright © Business Wire 2014

Mary Sullivan, 212-279-3115, ext. 114
Jennifer Mermel, 212-593-7972